Iovance Biotherapeutics (IOVA) Stock Forecast, Price Target & Predictions
IOVA Stock Forecast
Iovance Biotherapeutics stock forecast is as follows: an average price target of $12.40 (represents a 68.02% upside from IOVA’s last price of $7.38) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
IOVA Price Target
The average price target for Iovance Biotherapeutics (IOVA) is $12.40 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $17.00 to $10.00. This represents a potential 68.02% upside from IOVA's last price of $7.38.
IOVA Analyst Ratings
According to 10 Wall Street analysts, Iovance Biotherapeutics's rating consensus is 'Buy'. The analyst rating breakdown for IOVA stock is 0 'Strong Buy' (0.00%), 8 'Buy' (80.00%), 2 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Iovance Biotherapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Oct 24, 2024 | David Dai | UBS | $17.00 | $9.82 | 73.12% | 130.35% |
| Aug 09, 2024 | Benjamin Burnett | Stifel Nicolaus | $11.50 | $3.97 | 189.67% | 55.83% |
| Aug 09, 2024 | Colleen Kusy | Robert W. Baird | $12.00 | $3.97 | 202.27% | 62.60% |
| Jul 29, 2024 | Joseph Catanzaro | Piper Sandler | $10.00 | $9.25 | 8.11% | 35.50% |
| Jun 20, 2024 | Reni Benjamin | JMP Securities | $11.50 | $4.00 | 187.50% | 55.83% |
| May 31, 2024 | Benjamin Burnett | Stifel Nicolaus | $14.00 | $4.44 | 215.32% | 89.70% |
| Mar 14, 2024 | Joseph Catanzaro | Piper Sandler | $19.00 | $14.21 | 33.71% | 157.45% |
| Dec 08, 2022 | Madhu Kumar | Goldman Sachs | $6.00 | $7.17 | -16.32% | -18.70% |
| Nov 20, 2022 | Joseph Catanzaro | Piper Sandler | $11.00 | $6.62 | 66.16% | 49.05% |
| Aug 23, 2022 | Michael Ulz | Robert W. Baird | $12.50 | $5.75 | 117.39% | 69.38% |
| Jul 01, 2022 | Goldman Sachs | $18.00 | $11.04 | 63.04% | 143.90% | |
| May 27, 2022 | Stifel Nicolaus | $13.00 | $6.94 | 87.32% | 76.15% | |
| Apr 07, 2022 | Colleen Kusy | Robert W. Baird | $34.00 | $18.23 | 86.51% | 360.70% |
| Apr 05, 2022 | Colleen M. Kusy | Robert W. Baird | $30.00 | $16.56 | 81.16% | 306.50% |
| Jan 28, 2022 | Benjamin Burnett | Stifel Nicolaus | $25.00 | $15.04 | 66.22% | 238.75% |
| Jan 05, 2022 | Nick Abbott | Wells Fargo | $25.00 | $16.82 | 48.63% | 238.75% |
| May 19, 2021 | Peter Lawson | Barclays | $40.00 | $16.33 | 144.95% | 442.01% |
The latest Iovance Biotherapeutics stock forecast, released on Oct 24, 2024 by David Dai from UBS, set a price target of $17.00, which represents a 73.12% increase from the stock price at the time of the forecast ($9.82), and a 130.35% increase from IOVA last price ($7.38).
Iovance Biotherapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 7 |
| Avg Price Target | - | $17.00 | $13.57 |
| Last Closing Price | $7.38 | $7.38 | $7.38 |
| Upside/Downside | -100.00% | 130.35% | 83.88% |
In the current month, the average price target of Iovance Biotherapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Iovance Biotherapeutics's last price of $7.38. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 24, 2024 | UBS | Buy | Initialise | |
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 12, 2024 | Piper Sandler | Market Outperform | Market Outperform | Hold |
| Jul 29, 2024 | Piper Sandler | Overweight | Neutral | Downgrade |
| Jul 01, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Jun 20, 2024 | JMP Securities | Outperform | Outperform | Hold |
| May 24, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Mar 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Feb 20, 2024 | Chardan Capital | Buy | Buy | Hold |
| Dec 08, 2022 | Goldman Sachs | Buy | Neutral | Downgrade |
| Nov 20, 2022 | Piper Sandler | Neutral | Neutral | Hold |
| Oct 31, 2022 | Jefferies | Hold | Initialise | |
| Oct 31, 2022 | Piper Sandler | Overweight | Initialise | |
| Oct 31, 2022 | Wells Fargo | Overweight | Initialise | |
| Oct 31, 2022 | Cowen & Co. | Sector Weight | Initialise | |
| Oct 31, 2022 | Guggenheim | Buy | Initialise | |
| Jul 01, 2022 | Goldman Sachs | Buy | Buy | Hold |
| May 27, 2022 | Chardan Capital | Buy | Buy | Hold |
| May 24, 2022 | Goldman Sachs | Buy | Buy | Hold |
| Feb 25, 2022 | Chardan Capital | Buy | Buy | Hold |
Iovance Biotherapeutics's last stock rating was published by UBS on Oct 24, 2024. The company Initialise its IOVA rating from "null" to "Buy".
Iovance Biotherapeutics Financial Forecast
Iovance Biotherapeutics Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $469.00K | $238.00K | - |
| Avg Forecast | $58.55M | $58.55M | $58.55M | $58.55M | $143.38M | $123.61M | $104.63M | $88.17M | $71.51M | $53.79M | $24.59M | $2.03M | $1.44M | $4.50M | $3.91M | $222.22K |
| High Forecast | $64.30M | $64.30M | $64.30M | $64.30M | $157.44M | $135.73M | $114.89M | $91.70M | $76.82M | $53.80M | $24.59M | $2.05M | $2.31M | $4.94M | $4.29M | $244.01K |
| Low Forecast | $55.00M | $55.00M | $55.00M | $55.00M | $134.68M | $116.12M | $98.29M | $82.63M | $69.26M | $53.78M | $24.59M | $2.01M | $564.81K | $4.23M | $3.67M | $208.75K |
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 5 | 4 | 8 | 4 | 5 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.10% | 0.06% | - |
Iovance Biotherapeutics's average Quarter revenue forecast for Dec 23 based on 8 analysts is $1.44M, with a low forecast of $564.81K, and a high forecast of $2.31M. IOVA's average Quarter revenue forecast represents a 207.21% increase compared to the company's last Quarter revenue of $469.00K (Sep 23).
Iovance Biotherapeutics EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 5 | 4 | 8 | 4 | 5 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-118.36M | $-110.09M | $-110.86M |
| Avg Forecast | $35.13M | $35.13M | $35.13M | $35.13M | $86.03M | $74.17M | $62.78M | $52.90M | $42.91M | $32.27M | $14.76M | $1.22M | $864.50K | $2.70M | $2.35M | $133.33K |
| High Forecast | $38.58M | $38.58M | $38.58M | $38.58M | $94.46M | $81.44M | $68.93M | $55.02M | $46.09M | $32.28M | $14.76M | $1.23M | $1.38M | $2.96M | $2.58M | $146.41K |
| Low Forecast | $33.00M | $33.00M | $33.00M | $33.00M | $80.81M | $69.67M | $58.97M | $49.58M | $41.56M | $32.27M | $14.76M | $1.21M | $338.88K | $2.54M | $2.20M | $125.25K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | -43.84% | -46.94% | -831.42% |
undefined analysts predict IOVA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Iovance Biotherapeutics's previous annual EBITDA (undefined) of $NaN.
Iovance Biotherapeutics Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 5 | 4 | 8 | 4 | 5 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-113.76M | $-106.53M | $-103.88M |
| Avg Forecast | $6.79M | $1.27M | $363.92K | $-6.43M | $-75.75M | $-61.65M | $-67.86M | $-75.50M | $-80.23M | $-90.63M | $-107.20M | $-128.69M | $-130.64M | $-137.87M | $-151.10M | $-171.95M |
| High Forecast | $7.66M | $1.44M | $410.31K | $-5.92M | $-69.78M | $-56.78M | $-62.51M | $-66.79M | $-61.72M | $-83.49M | $-98.74M | $-118.54M | $-118.77M | $-127.00M | $-139.19M | $-158.40M |
| Low Forecast | $6.26M | $1.17M | $335.23K | $-7.25M | $-85.40M | $-69.50M | $-76.51M | $-90.02M | $-92.58M | $-102.18M | $-120.86M | $-145.09M | $-139.55M | $-155.44M | $-170.36M | $-193.87M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.83% | 0.70% | 0.60% |
Iovance Biotherapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. IOVA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Iovance Biotherapeutics SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 5 | 4 | 8 | 4 | 5 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $26.96M | $21.93M | $28.12M |
| Avg Forecast | $1.10B | $1.10B | $1.10B | $1.10B | $2.69B | $2.32B | $1.97B | $1.66B | $1.34B | $1.01B | $461.99M | $38.12M | $27.06M | $84.53M | $73.43M | $4.17M |
| High Forecast | $1.21B | $1.21B | $1.21B | $1.21B | $2.96B | $2.55B | $2.16B | $1.72B | $1.44B | $1.01B | $461.99M | $38.49M | $43.30M | $92.82M | $80.63M | $4.58M |
| Low Forecast | $1.03B | $1.03B | $1.03B | $1.03B | $2.53B | $2.18B | $1.85B | $1.55B | $1.30B | $1.01B | $461.99M | $37.74M | $10.61M | $79.40M | $68.98M | $3.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.32% | 0.30% | 6.74% |
Iovance Biotherapeutics's average Quarter SG&A projection for Dec 23 is $27.06M, based on 8 Wall Street analysts, with a range of $10.61M to $43.30M. The forecast indicates a 0.37% rise compared to IOVA last annual SG&A of $26.96M (Sep 23).
Iovance Biotherapeutics EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 4 | 4 | 4 | 3 | 3 | 3 | 5 | 9 | 4 | 5 | 4 | 8 | 4 | 5 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.46 | $-0.47 | $-0.49 |
| Avg Forecast | $0.02 | - | - | $-0.02 | $-0.25 | $-0.20 | $-0.22 | $-0.25 | $-0.26 | $-0.30 | $-0.35 | $-0.42 | $-0.43 | $-0.45 | $-0.50 | $-0.57 |
| High Forecast | $0.03 | - | - | $-0.02 | $-0.23 | $-0.19 | $-0.21 | $-0.22 | $-0.20 | $-0.28 | $-0.33 | $-0.39 | $-0.39 | $-0.42 | $-0.46 | $-0.52 |
| Low Forecast | $0.02 | - | - | $-0.02 | $-0.28 | $-0.23 | $-0.25 | $-0.30 | $-0.31 | $-0.34 | $-0.40 | $-0.48 | $-0.46 | $-0.51 | $-0.56 | $-0.64 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.01% | 0.94% | 0.86% |
According to undefined Wall Street analysts, Iovance Biotherapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to IOVA previous annual EPS of $NaN (undefined).
Iovance Biotherapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| HEPA | Hepion Pharmaceuticals | $0.52 | $70.00 | 13361.54% | Buy |
| CVAC | CureVac | $2.95 | $29.00 | 883.05% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| IOVA | Iovance Biotherapeutics | $7.81 | $12.40 | 58.77% | Buy |
| SRPT | Sarepta Therapeutics | $125.76 | $187.20 | 48.85% | Buy |
| KRYS | Krystal Biotech | $169.04 | $210.33 | 24.43% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| PTCT | PTC Therapeutics | $47.02 | $48.00 | 2.08% | Hold |